Medmain Speaks

~Official Blog~

[Announcement of Publication] In July 2021, Our Paper Presented at the Conference of Medical Imaging with Deep Learning (MIDL) was Published in the Proceedings of Machine Learning Research - A Pivotal Investigation of Fundamental Technology for Transfer Learning -

Partial Transfusion: on the Expressive Influence of Trainable Batch Norm Parameters for Transfer Learning

Posted by Maya Friday, November 12, 2021

Successful Development of Deep Learning Models to Classify Gastric Signet Ring Cell Carcinoma in Histopathological Whole Slide Images - Published in Technology in Cancer Research and Treatment -

Deep Learning Models for Gastric Signet Ring Cell Carcinoma Classification in Whole Slide Images

Posted by Maya Thursday, November 11, 2021

Successful Development of an Artificial Intelligence (Deep Learning) Model to Discriminate Pancreatic Adenocarcinoma in Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Biopsy Histopathological Specimens - Published in Scientific Reports -

A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy

Posted by Maya Friday, May 21, 2021

Successful Development of an Artificial Intelligence Model Using Deep Learning Approach to Establish Histological Sub-classification of Lung Cancer in Biopsy Specimens Whole Slide Images - Published in Scientific Reports -

Medmain Co., Ltd. (Headquarters: Fukuoka Prefecture, Fukuoka City, CEO: Osamu Iizuka, hereinafter referred to “Medmain”), a provider of “PidPort” pathological diagnosis support solutions, has succeeded in developing an artificial intelligence model to classify lung cancer subtypes in lung biopsy specimens using Deep Learning, which enables the sub-classification of the macarcinoma). A dissertation

Posted by Maya Tuesday, May 11, 2021

We have raised 1.1 billion yen in funding led by several hospital groups!

We a happy to announce that we have raised approximately 1.1 billion yen through a private placement of new shares by multiple hospital groups, venture capitalists, businesses, and private investors. With the recent demand for the rapid development of a diagnostic system after the COVID-19 pandemic, Medmain Inc. will continue to support medical professionals across the country, especially those who are on the front lines of pathology diagnosis. About Fundraising

Posted by Naoko Monday, August 24, 2020